Ruxolitinib for Disease-Related Splenomegaly or Symptoms in Adults with Myelofibrosis (TA289)

Technology Appraisal Guidance No. 289

Source: National Institute for Health and Care Excellence

NOTE: This guidance has been replaced by NICE technology appraisal guidance 386

1. Guidance

1.1 Ruxolitinib is not recommended within its marketing authorisation, that is, for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

1.2 People currently receiving ruxolitinib should be able to continue treatment until they and their clinician consider it appropriate to stop.


The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at http://guidance.nice.org.uk/TA289

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: nice@nice.org.uk

Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis

Issue Date: June 2013


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in